PROQR THERAPEUTICS N.V. news, videos and press releases - Page 3
For more news please use our advanced search feature.
PROQR THERAPEUTICS N.V. - More news...
PROQR THERAPEUTICS N.V. - More news...
- ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
- ProQR Announces Highlights from Analyst Event
- ProQR to Webcast Virtual Analyst Event on November 18
- ProQR Announces Upcoming Investor Conferences in November and December
- ProQR Announces Third Quarter 2021 Operating and Financial Results
- ProQR Appoints Theresa Heggie as Chief Commercial Officer
- ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
- ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
- ProQR Announces Virtual Presentation at EURETINA 2021
- ProQR Announces Upcoming Investor Conferences
- ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Ophthalmology Virtual Conference
- ProQR Announces Second Quarter 2021 Operating and Financial Results
- ProQR to Present at Upcoming JMP Securities Life Sciences Conference
- ProQR Announces First Quarter 2021 Operating and Financial Results
- ProQR Therapeutics and Yarrow Biotechnology, an RTW Investments, LP Incubated Company, Announce Exclusive Worldwide License and Discovery Collaboration for Undisclosed Target
- ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021
- ProQR Announces Participation in Upcoming Kempen Life Sciences Conference
- ProQR Announces Annual Meeting of Shareholders
- ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10
- ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
- ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021
- ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares
- ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
-
ProQR Therapeutics N.V. - PRQR Stock Chart Technical Analysis for 03-25-2021
- ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials
- ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
- ProQR Announces Webcast of Presentation at Upcoming HC Wainwright Global Life Sciences Conference
- ProQR Announces Fourth Quarter and Full Year 2020 Operating and Financial Results
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
- ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10
